Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1600 1635 1636 4100
This examiner grants 71% of resolved cases
Shabana Shabbeer Meyering has overseen 68 resolved cases in Tech Center 4100. The 70.6% allowance rate indicates the likelihood of grant for applications assigned to Art Unit 1600. This rate suggests that the examiner is willing to identify patentable subject matter when technical requirements are met.
The 42.3% interview lift is a factor for practitioners to consider. This lift shows a correlation between examiner engagement and successful outcomes, suggesting that verbal discussions are effective at resolving disagreements. In Art Unit 1600, the interview is an activity that can improve the odds of a favorable result by 42.3%.
The median of 1105 days to allowance provides a benchmark for the duration of the patent acquisition process. This timeline indicates that applicants should plan for a multi-year engagement. By combining the 70.6% allowance rate with the 42.3% interview lift, practitioners can develop a strategy for navigating this examiner's docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18510297 | COMBINED TRANSPOSON-MEDIATED INTEGRATION AND TARGETED INTEGRATION OF NUCLEIC ACIDS INTO HOST CELLS | Non-Final OA | Genentech, Inc. |
| 18467442 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | Final Rejection | UNIVERSITY OF ROCHESTER |
| 17701013 | MULTI-INPUT MIRNA SENSING WITH CONSTITUTIVE ERNS TO REGULATE MULTI-OUTPUT GENE EXPRESSION IN MAMMALIAN CELLS | Non-Final OA | Massachusetts Institute of Technology |
| 18129923 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17810022 | METHODS FOR THE TREATMENT OF EPILEPSY | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 17597351 | METHODS FOR THE TREATMENT OF EPILEPSY | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 18175394 | ENGINEERED MICROALGAE FEED TO IMPROVE HONEY BEE PATHOGEN RESISTANCE AND NUTRITION | Non-Final OA | The United States of America, as represented by The Secretary of Agriculture |
| 17995568 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 18390880 | VARIANT-SPECIFIC EXOGENOUS DNA TEMPLATE-FREE CORRECTION OF PATHOGENIC VARIANTS | Non-Final OA | Hadasit Medical Research Services and Development Ltd. |
| 18554286 | CANCER TREATMENT BY TARGETING PROTEINS OR INTERACTIONS OF EPHRINB-RGS3-KIF20A-SEPT7 AXIS | Non-Final OA | CITY OF HOPE |
| 18734879 | Guide Strand Library Construction and Methods of Use Thereof | Non-Final OA | Pioneer Biolabs, LLC |
| 18688563 | PHARMACEUTICAL COMPOSITION UTILIZING BORNAVIRUS VECTOR | Non-Final OA | NATIONAL UNIVERSITY CORPORATION SHIGA UNIVERSITY OF MEDICAL SCIENCE |
| 18248363 | HOMOGENEOUS BETA-1,3-GLUCAN/NUCLEIC ACID COMPLEXES AND USE THEREOF | Non-Final OA | The University of Kitakyushu |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy